Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Guangmei Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8822-2657; OpenAlex author ID A5100462457. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 4

  1. circ-1584 selectively promotes the antitumor activity of the oncolytic virus M1 on pancreatic cancer. Co-author DOI 10.1016/j.omton.2024.200919↗
  2. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Co-author DOI 10.1016/j.canlet.2024.216697↗
  3. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.12.018↗
  4. Triptolide cooperates with Cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Last author DOI 10.1097/mpa.0b013e31824abdc0↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Cai · 3 shared papers, 2021–2025 · strength 0.52
  2. Fengxiao Xie · 2 shared papers, 2021–2024 · strength 0.29
  3. Xin Huang · 2 shared papers, 2021–2024 · strength 0.29
  4. Shengping Li · 2 shared papers, 2021–2024 · strength 0.29
  5. Chaobin He · 2 shared papers, 2021–2024 · strength 0.29
  6. Shuxin Sun · 2 shared papers, 2021–2024 · strength 0.29
  7. Taofang Hao · 1 shared paper, 2025 · strength 0.23
  8. Jun X. Hu · 1 shared paper, 2025 · strength 0.23
  9. Jun Wang · 1 shared paper, 2024 · strength 0.18
  10. Haiyan Hu · 1 shared paper, 2012 · strength 0.03
  11. Wenbo Zhu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.